Qiagen N.V. Common Shares (NY:QGEN)

45.15 +0.40 (+0.89%)

Delayed Quote Updated: 12:03 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Earnings Preview: Qiagen ↗

February 05, 2024

Via Benzinga

Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion ↗

January 17, 2024

Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing...

Via Benzinga

Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects ↗

January 03, 2024

QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in

Via Benzinga

Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock ↗

December 07, 2023

Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics.

Via Benzinga

Where Qiagen Stands With Analysts ↗

December 07, 2023

Via Benzinga

These Companies Helped The German DAX Index Hit Its All-time High ↗

December 06, 2023

The DAX 40 index surged to its all-time high on Tuesday, continuing the remarkable rally that started on October 23rd. The index, which tracks the 40 biggest companies in Germany, soared to a high of...

Via Talk Markets

Analyst Expectations for Qiagen's Future ↗

November 02, 2023

Via Benzinga

Preview: Qiagen's Earnings ↗

October 27, 2023

Via Benzinga

Analyst Expectations for Qiagen's Future ↗

October 17, 2023

Via Benzinga

Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends ↗

October 31, 2023

Qiagen NV's (NASDAQ: QGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the

Via Benzinga

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

October 26, 2023

From Myriad Genetics, Inc.

Via GlobeNewswire

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

Will Chart Analysts Notice Bad Omen on Qiagen's Chart ↗

April 11, 2023

Via Benzinga

Earnings Scheduled For October 30, 2023 ↗

October 30, 2023

Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 19, 2023

During Tuesday's session, 275 companies made new 52-week lows.

Via Benzinga

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

July 26, 2023

From Bio-Rad Laboratories, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗

September 12, 2023

Via Benzinga

The 3 Most Promising Biotech Stocks to Buy Now ↗

March 21, 2023

With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now.

Via InvestorPlace

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

March 13, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

March 09, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

March 01, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework

February 14, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

February 07, 2023

From QIAGEN N.V.

Via Business Wire

Genetic Technologies Shares Jump After Strategic Alliance With Qiagen ↗

February 01, 2023

Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia.

Via Benzinga

QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs

January 17, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

January 17, 2023

From QIAGEN N.V.

Via Business Wire

Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories ↗

January 09, 2023

Bloomberg

Via Benzinga

QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics ↗

January 09, 2023

Via Benzinga

QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies

January 09, 2023

From QIAGEN

Via Business Wire

QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases

January 05, 2023

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.